The Prognostic Value of Ki-67, p53, Epidermal Growth Factor Receptor, 1p36, 9p21, 10q23, and 17p13 in Skull Base Chordomas
The Prognostic Value of Ki-67, p53, Epidermal Growth Factor Receptor, 1p36, 9p21, 10q23, and 17p13 in Skull Base Chordomas
复制标题
DOI：
10.1043/2009-0380-oa.1
复制
发表时间：
2010-08-01
影响因子：
4.6
通讯作者：
Seethala, Raja R.
中科院分区：
文献类型：
--
作者：
Horbinski, Craig;Oakley, Gerard J.;Seethala, Raja R.
背景。-颅底脊索瘤是一种罕见的、局部侵袭性的、脊索源性肿瘤，其解剖学相关的生物标志物尚未得到很好的建立。评估脊索瘤中新发现的分子改变是否具有与Ki-67增殖指数相似的预后意义。我们对28例原发性斜坡脊索瘤进行了回顾性研究。Ki-67增殖指数5%或以上，p53积聚，表皮生长因子受体表达分别见于32%，44%和8%的脊索瘤。1 p杂合性缺失（洛）和/或1 p36半合子缺失见于30%的肿瘤，而9 p洛和/或9 p21纯合性缺失见于21%的肿瘤。10 q23和17 p13的杂合性丢失分别为57%和52%。Ki-67增殖指数≥ 5%和9 p洛与总生存期较短显著相关，而荧光原位杂交检测的9 p21纯合缺失接近显著性。未发现p53或表皮生长因子受体表达、1 p36半合子缺失或1 p、10 q23或17 p13的洛合性缺失与生存相关。Ki-67增殖指数升高或9 p21缺失的脊索瘤可能具有更侵袭性的临床病程和更短的生存期。因此，这些生物标志物可用于改善治疗分层。(Arch Pathol Lab Med. 2010; 134：1170-1176）
Context.-Skull base chordomas are rare, locally aggressive, notochord-derived neoplasms for which prognostically relevant biomarkers are not well established.Objective.-To evaluate whether newly discovered molecular alterations in chordomas have prognostic significance similar to what has been described regarding Ki-67 proliferation index.Design.-We conducted a retrospective study of 28 cases of primary clival chordomas.Results.-Ki-67 proliferation index 5% or more, p53 accumulation, and epidermal growth factor receptor expression were seen in 32%, 44%, and 8% of chordomas, respectively. 1p loss of heterozygosity ( LOH) and/or 1p36 hemizygous deletion was seen in 30% of tumors, while 9p LOH and/or 9p21 homozygous deletion was seen in 21% of cases. Loss of heterozygosity at 10q23 and 17p13 were identified in 57% and 52% of cases, respectively. Ki-67 proliferation index 5% or more and 9p LOH were significantly associated with a shorter overall survival, while homozygous deletion at 9p21 via fluorescence in situ hybridization approached significance. No correlation with survival was found for p53 or epidermal growth factor receptor expression, 1p36 hemizygous deletion, or LOH at 1p, 10q23, or 17p13.Conclusions.-Chordomas with elevated Ki-67 proliferation index or deletion at 9p21 may be at risk for a more aggressive clinical course and shorter survival. These biomarkers may thus be used to improve therapeutic stratification. (Arch Pathol Lab Med. 2010; 134: 1170-1176)